The First U.S. Broad-Spectrum Botanical Antiviral Candidate

Innovating Nature-Inspired Medicines to Address the World’s Most Challenging Diseases.

Partner With HerbGreen A Different Approach

Illustrative animation: a generic leaf form drawn as a rotating cloud of text characters, scanned left to right by a vertical line; a trace beneath shows the drawing’s own outline profile.

At a Glance

Lead asset
HerbX, an investigational, proprietary multi-component botanical drug candidate being developed for respiratory viral infections
Target indication
Respiratory viral infections, including influenza and COVID-19
Stage
Preclinical; advancing IND-enabling strategy; FDA Type C meeting completed
Evidence to date
In-vitro activity against SARS-CoV-2, influenza A, RSV and dengue virus; 23 uncontrolled, retrospectively documented cases; no controlled clinical studies yet
Next milestone
IND submission, targeted for Q1–Q2 2027
Intellectual property
Patent pending: utility patent application filed

What if the next breakthrough in medicine doesn’t begin with a newly synthesized molecule—but with the extraordinary complexity of nature?

At HerbGreen, we believe the future of medicine lies not only in discovering new molecules, but also in unlocking the therapeutic potential of nature’s sophisticated biological systems.

We are pioneering a new approach to pharmaceutical innovation—developing proprietary, multi-component botanical formulations into investigational medicines designed to address significant unmet medical needs.

Our ambition is not simply to develop one drug. It is to establish a new generation of botanical pharmaceutical innovation.

News

  1. HerbX reduced infectious SARS-CoV-2, influenza A, RSV and dengue virus in independent laboratory testing

    In a 30-minute direct-contact suspension assay conducted by an independent U.S. laboratory, HerbX reduced the infectious titer of all four viruses tested, by more than 99% for three of the four.

    Reduction in infectious virus after 30 minutes of direct contact, laboratory assay
    SARS-CoV-2 COVID-19
    >99%
    Influenza A H1N1
    >99.9%
    RSV Respiratory syncytial virus
    >90%
    Dengue virus Type 2 (DENV-2)
    >99.9%

    The panel spanned four virus families: Coronaviridae (SARS-CoV-2), Orthomyxoviridae (influenza A H1N1), Pneumoviridae (RSV) and Flaviviridae (DENV-2). All four are enveloped viruses. DENV-2, a mosquito-borne flavivirus, falls outside the respiratory indications for which HerbX is being developed.

    Activity was observed in each of the four HerbX production lots tested, manufactured between 2024 and 2026. Consistent biological activity from lot to lot is a key consideration in the development of multi-component botanical drugs.

    Reductions in infectious titer ranged from greater than 90% (RSV) to greater than 99.9% (influenza A and DENV-2). The assay measures direct inactivation of virus in suspension; it does not assess antiviral activity in infected cells or in vivo, and the results do not establish clinical efficacy. Further nonclinical and controlled clinical studies are required. HerbX is an investigational drug candidate and has not been approved by the FDA.

A Different Approach to Drug Discovery

Nature Is Our Starting Point. Therapeutic Efficacy Is Our Goal.

Illustrative animation: one molecule-like figure drawn in text characters is joined by many others into a single rotating system; a trace beneath gains one peak per figure.

  1. For decades, pharmaceutical innovation has achieved extraordinary advances through the discovery and development of individual molecules.

  2. But nature offers another possibility: complex combinations of naturally occurring compounds that may possess valuable therapeutic properties.

  3. At HerbGreen, our core competence is botanical formulation innovation—the scientific design and development of sophisticated, multi-component botanical therapeutics.

We bring together botanical knowledge, modern analytical science, pharmaceutical development, and clinical research to investigate new therapeutic possibilities.

  • Botanical knowledge
  • Modern analytical science
  • Pharmaceutical development
  • Clinical research

Illustrative: four text-drawn signal lines combine into one summed line.

We believe medicines should not be judged by whether they originate in nature or a laboratory. What ultimately matters is whether they are safe, effective, and capable of improving patients’ lives.

The Case That Started Everything

He was getting worse on the treatment his doctor prescribed. Then he took an early prototype of HerbX.

  1. In March 2023, a 59-year-old man came down with COVID-19. For seven days he had a persistent fever and a worsening cough, and Tylenol wasn’t helping.

  2. On March 30, he saw his doctor. A CT scan showed an infection in the upper part of his lung, and he was started on a five-day course of IV Rocephin (ceftriaxone) and dexamethasone.

  3. Two days in, he was getting worse, not better. His fever reached about 104°F (40°C), he was struggling to breathe, and he was too weak to walk. Emergency hospital care was being considered.

  4. On April 1, he took his first dose of an early prototype of HerbX. Within 48 hours, he had made a full recovery.

Those 48 hours are why HerbGreen exists.

Today, HerbX is being investigated as a potential antiviral therapeutic, with laboratory evidence of activity against influenza A H1N1, SARS-CoV-2, RSV and dengue virus, and an ongoing FDA-engaged development program.

One patient’s recovery became a scientific mission.

Introducing HerbX

HerbX is an investigational drug candidate and has not been approved by the FDA.

The First U.S. Broad-Spectrum Antiviral Botanical Drug Candidate. A New Possibility in Antiviral Medicine.

Respiratory viral infections—including influenza and COVID-19—continue to create substantial challenges for patients and healthcare systems worldwide.

Although antiviral treatments exist for certain infections, significant unmet needs remain for therapies with broader antiviral coverage.

HerbX, HerbGreen’s lead investigational botanical drug candidate, is being developed to explore the potential of a proprietary multi-component formulation against respiratory viral infections.

Our development journey began with observations in patients rather than conventional laboratory screening.

Illustrative animation: many near-identical traces drawn in text characters, stacked in depth; one highlighted trace moves through the stack.

Illustrative visualization — not assay data.

Evidence to Date

Data sourceWhat was reportedDetails and limitations
In vitro · four viruses, direct contact In October 2026, independent U.S. laboratory testing found that HerbX reduced infectious SARS-CoV-2, influenza A (H1N1), RSV and dengue virus (DENV-2) in a 30-minute direct-contact assay. Reductions in infectious virus: SARS-CoV-2 >99%; influenza A >99.9%; RSV >90%; DENV-2 >99.9%, across four production lots made 2024–2026. Measures inactivation of virus on contact, outside cells; does not show activity in the body.
In vitro · influenza A H1N1 Recent preliminary in-vitro studies have demonstrated antiviral activity against influenza A H1N1. Concentration-dependent activity in MDCK cells across multiple tested lots: EC50 4.6–4.7 μg/mL; EC90 8.4 μg/mL (reported 1-log10 viral-yield reduction); SI50 >5.3. In separate reported cell-based testing, aqueous HerbX showed a CC50 of ≥1,200 μg/mL.
Retrospective case records HerbGreen has retrospectively documented 23 individuals with laboratory-confirmed COVID-19, influenza, or respiratory illnesses of undetermined viral origin. The records describe reported symptom improvement following use of the botanical preparation, with no adverse effects reported in the available case documentation. Uncontrolled, retrospective observations; not a clinical study. Twelve of these cases, the earliest documented, have been submitted to FDA.

These early findings provide a foundation for further investigation. HerbX’s clinical safety and efficacy remain to be established through controlled studies.

From Human Observation to Scientific Investigation. From Botanical Innovation to Clinical Development.

Advancing Through FDA-Regulated Drug Development

From Discovery Toward Clinical Validation

  1. Discovery
  2. Type C meetingCompleted
  3. IND-enabling strategyAdvancing
  4. Clinical validation

Schematic: a line runs from Discovery through a completed Type C meeting to an IND-enabling strategy in progress; the segment toward Clinical Validation is dashed.

HerbGreen has engaged extensively with the U.S. Food and Drug Administration, including completion of a Type C meeting addressing the HerbX botanical drug-development program.

We are advancing our investigational new drug (IND)-enabling strategy, incorporating regulatory feedback into our scientific, manufacturing, and clinical-development planning.

Our priorities include:

  1. Strengthening the scientific and safety package supporting clinical investigation.
  2. Developing botanical-specific chemistry, manufacturing, and controls (CMC) capabilities.
  3. Establishing reproducible product quality and manufacturing processes.
  4. Preparing for controlled human clinical studies.
  5. Building the infrastructure needed to support future botanical drug candidates.

Development Roadmap

Target indication: respiratory viral infections, including influenza and COVID-19.

  1. FDA Type C meetingCompletedHerbX-specific guidance received on CMC and in-vitro studies.
  2. CMC and manufacturing readinessFrom Q4 2026Manufacturing site secured, with agricultural processing permits in place. Establishing a company-controlled botanical manufacturing prototype, quality systems and reproducible clinical-trial material.
  3. IND submissionTarget Q1–Q2 2027Complete the IND-enabling package and submit to FDA for clinical trial authorization.
  4. Phase 2a clinical trialTarget Q3 2027A controlled, approximately 100-patient, multi-virus respiratory infection study evaluating symptom reduction and viral-load changes, subject to FDA review and clinical readiness.
  5. New Drug Application (NDA)Long-term objectivePursue FDA approval through the NDA pathway, targeting over-the-counter availability, subject to successful clinical development and FDA authorization.

Milestones and timing are forward-looking and may change; see forward-looking statements.

We are committed to developing medicines whose value is established through scientific evidence—not simply their natural origin.

Innovation From the Source

Building a Vertically Integrated Botanical Drug Platform

Botanical medicines present unique scientific and manufacturing challenges. Their complexity requires careful control of raw materials, processing methods, formulation consistency, and product quality.

  1. proprietary botanical sourcing
  2. formulation design
  3. analytical characterization
  4. quality systems
  5. capital-efficient prototype manufacturing

Schematic: text-character particles enter a vertical column, pass through five labelled stages that make them progressively ordered, and leave as uniform units.

HerbGreen is developing a vertically integrated pharmaceutical platform designed to address those challenges.

Our approach connects proprietary botanical sourcing, formulation design, analytical characterization, quality systems, and capital-efficient prototype manufacturing.

By developing these capabilities within HerbGreen, we aim to strengthen product consistency, protect proprietary knowledge, and establish a scalable foundation for future pharmaceutical innovation.

Intellectual Property

Patent pending: a utility patent application covering proprietary HerbX technology has been filed. HerbGreen also has proprietary formulation know-how and is building company-controlled manufacturing and quality systems.

Standardization & CMC

HerbGreen is building company-controlled sourcing, processing, analytical characterization and formulation-consistency capabilities, including phytochemical profiling, HPTLC standardization and chemical-stability testing. A site has been secured, with agricultural processing permits in place, for a company-controlled manufacturing prototype intended to produce reproducible clinical-trial material.

We believe control over the source is the beginning of control over the medicine.

Beyond HerbX

One Discovery Is Only the Beginning.

HerbX is our first investigational drug candidate—but our vision extends far beyond antiviral medicine.

We aspire to build a biotechnology company capable of repeatedly discovering, designing, and developing innovative botanical formulations for important unmet medical needs.

Illustrative animation: a dome of text characters grows outward in a golden-angle spiral; one central point is marked HerbX.

Our long-term ambition is to establish a portfolio of differentiated botanical therapeutics supported by intellectual property, reproducible manufacturing, scientific evidence, and clinical validation.

We are not building a company around one botanical formula. We are building a company whose defining strength is the ability to innovate botanical medicines again and again.

Changing the Perception of Natural Medicine

Illustrative: the outlined word BELIEVE, drawn in text characters, is converted left to right into the solid word EVIDENCE.

We Are Not Asking the World to Believe. We Are Building the Evidence.

Natural medicine is often associated with general wellness, uncertain efficacy, or limited scientific validation.

HerbGreen is working toward a different future.

A future where botanical medicines are evaluated by the strength of their evidence, the consistency of their quality, and the meaningful benefits they demonstrate for patients.

  • We want physicians to recognize HerbGreen for credible clinical evidence.
  • We want scientists to recognize HerbGreen for pharmaceutical innovation.
  • We want patients to associate HerbGreen with trust, proven therapeutic effectiveness, and medicines that can make a life-changing difference.
  • And we want investors and partners to recognize HerbGreen as a company building a long-term botanical pharmaceutical innovation platform.

We are not asking the world to lower its standards for natural medicine. We are working to develop natural medicines that meet the world’s highest standards.

Partner With HerbGreen

Help Shape the Future of Botanical Medicine.

Breakthrough innovation requires vision, scientific discipline, and partners willing to explore new possibilities.

HerbGreen welcomes conversations with biotechnology investors, pharmaceutical companies, research institutions, and strategic partners who share our ambition to advance botanical drug discovery.

Together, we can explore a new frontier of pharmaceutical innovation.

Request investor materials
I’m reaching out as

Email your request to

Compose email

Investor materials are provided only to qualified prospective investors. Nothing on this website constitutes an offer to sell, or a solicitation of an offer to buy, any securities.

Illustrative animation: a looping figure drawn in text characters drifts, then settles into a still circle.